---
title: "Kisqali (ribociclib), all indications: Drug interactions questions"
description: "Drug interactions questions on Kisqali (ribociclib) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: What drug interactions does Kisqali have? Can Kisqali be taken with strong CYP3A inducers such as rifampin? Does Kisqali affect other drugs metabolized by CYP3A? Can Kisqali be taken with other drugs that prolong the QT interval? 1 further question follow. 5 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/kisqali/drug-interactions"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Kisqali (ribociclib), all indications: Drug interactions questions

Manufacturer: Novartis Pharmaceuticals Corporation  
Prescribing information: [Kisqali](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf)  
Indication pages: [HR-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer)

## Drug interactions

<a id="kisqali-drug-interactions"></a>

### What drug interactions does Kisqali have?

> “• CYP3A Inhibitors: Avoid concomitant use of KISQALI with strong
> CYP3A inhibitors. If strong inhibitors cannot be avoided, reduce KISQALI 
> dose. (2.2, 7.1) 
> • CYP3A4 Inducers: Avoid concomitant use of KISQALI with strong
> CYP3A inducers. (7.2) 
> • CYP3A Substrates: The dose of CYP3A substrates may need to be reduced 
> when given concurrently with KISQALI. (7.3) 
> • Drugs Known to Prolong QT Interval: Avoid concomitant use of drugs
> known to prolong QT interval, such as anti-arrhythmic medicines. (7.4)”

Source: [KISQALI: Prescribing information, page 1, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=1)

> “Inform patients to avoid strong CYP3A inhibitors, strong CYP3A inducers, and drugs known to prolong the QT interval”

Source: [KISQALI: Prescribing information, page 31, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=31)

Note: The first passage is from the Highlights of the Prescribing Information; the second is from its Patient Counseling Information.

<a id="kisqali-cyp3a-inducers"></a>

### Can Kisqali be taken with strong CYP3A inducers such as rifampin?

> “Coadministration of strong CYP3A inducers decreases the plasma exposure of ribociclib [see Clinical Pharmacology 
> (12.3)]. Avoid concomitant use of strong CYP3A inducers and consider an alternate concomitant medication with no or 
> minimal potential to induce CYP3A.”

Source: [KISQALI: Prescribing information, page 17, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=17)

> “CYP3A Inducers: Following a single 600 mg dose of KISQALI with rifampicin (a strong CYP3A4 inducer) at 600 mg daily 
> for 14 days, ribociclib Cmax decreased by 81% and AUCinf decreased by 89%, while LEQ803 Cmax increased 1.7-fold and 
> AUCinf decreased by 27% compared to ribociclib alone.”

Source: [KISQALI: Prescribing information, page 21, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=21)

Note: The label names the inducer studied as rifampicin, another name for rifampin.

<a id="kisqali-cyp3a-substrates"></a>

### Does Kisqali affect other drugs metabolized by CYP3A?

> “Coadministration of sensitive CYP3A4 substrates with multiple doses of KISQALI increases the substrate exposure [see 
> Clinical Pharmacology (12.3)]. For CYP3A substrates where minimal increases in the concentration may increase CYP3A 
> substrate adverse reactions, monitor for increased adverse reactions of the CYP3A substrate during treatment with 
> KISQALI.  The dose of the sensitive CYP3A substrate may need to be reduced as KISQALI can increase its exposure.”

Source: [KISQALI: Prescribing information, page 17, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=17)

> “CYP3A4 and CYP1A2 Substrates: In a cocktail study with midazolam (sensitive CYP3A4 substrate) multiple doses of 
> ribociclib (400 mg once daily for 8 days) increased midazolam Cmax by 2.1-fold and increased AUCinf by 3.8-fold compared 
> to midazolam alone. Administration of KISQALI 600 mg once daily is predicted to increase midazolam Cmax and AUC by 
> 2.4-fold and 5.2-fold, respectively.”

Source: [KISQALI: Prescribing information, page 21, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=21)

<a id="kisqali-qt-prolonging-drugs"></a>

### Can Kisqali be taken with other drugs that prolong the QT interval?

> “Avoid coadministration of KISQALI with products with a known potential to prolong QT interval, such as antiarrhythmic 
> drugs and other drugs that are known to prolong the QT interval. If concomitant use cannot be avoided, monitor ECG when 
> initiating, during concomitant use, and as clinically indicated [see Warnings and Precautions (5.3), Clinical Pharmacology 
> (12.2)].”

Source: [KISQALI: Prescribing information, page 17, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=17)

<a id="kisqali-acid-reducers"></a>

### Do acid-reducing drugs affect Kisqali absorption?

> “Gastric pH-Elevating Agents: Coadministration of ribociclib with drugs that elevate the gastric pH is not predicted to alter 
> ribociclib absorption.”

Source: [KISQALI: Prescribing information, page 21, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=21)

## Related pages
- [Medical information: Kisqali (ribociclib): All indications](https://www.evicenter.com/medical-information/kisqali)
- [Indication](https://www.evicenter.com/medical-information/kisqali/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/kisqali/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/kisqali/safety)
- [Specific populations](https://www.evicenter.com/medical-information/kisqali/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/kisqali/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/kisqali/storage-and-supply)
